Vemlidy is a prescription antiviral medication used to treat chronic hepatitis B virus (HBV) infection. It contains the active ingredient tenofovir alafenamide (TAF), taken as a single 25 mg tablet once daily with food. The drug is approved for adults and children aged 6 and older who weigh at least 25 kg (about 55 pounds), specifically for those whose liver disease has not yet progressed to decompensation, meaning the liver still functions reasonably well despite the infection.
How Vemlidy Works
Hepatitis B is a virus that replicates inside liver cells. Vemlidy is designed to get inside those same cells and block the virus from copying itself. Once swallowed, the drug enters liver cells both through passive diffusion and through specific transport channels on the cell surface. Inside the cell, enzymes convert it into its active form, which then interferes with the virus’s ability to replicate its DNA. This doesn’t eliminate the virus entirely, but it suppresses viral levels enough to reduce liver damage and slow disease progression.
This is a long-term treatment. Chronic hepatitis B typically requires ongoing antiviral therapy, often for years or indefinitely, because the virus is never fully cleared from the body. Stopping the medication can trigger a dangerous flare of the infection.
How It Differs From Older Tenofovir (Viread)
Vemlidy is a newer formulation of tenofovir, developed largely to reduce side effects associated with the older version, tenofovir disoproxil fumarate (sold as Viread). Both drugs deliver the same active compound to liver cells, but Vemlidy does so more efficiently, meaning lower levels of the drug circulate through the rest of the body. The practical result is less impact on bones and kidneys.
Clinical trial data at 96 weeks shows the difference clearly. Among patients taking Viread, 16% experienced a shift from normal bone density to osteopenia at the hip, compared to just 6% on Vemlidy. At the spine, 10% of Viread patients progressed from osteopenia to osteoporosis versus 7% on Vemlidy. In a separate study, patients who switched from Viread to Vemlidy actually saw improvements in hip and spine bone density over 48 weeks, while those who stayed on Viread continued to lose density.
Vemlidy also has a broader margin for kidney function. It can be used in patients with a creatinine clearance as low as 15 mL per minute, including those on hemodialysis. No dose adjustment is needed across that range. The older formulation requires more intensive kidney monitoring and carries greater risk of renal side effects.
Common Side Effects
In clinical trials involving patients with chronic hepatitis B and compensated liver disease, the most frequently reported side effects at 48 weeks were:
- Headache: 9% of patients
- Abdominal pain: 7%
- Fatigue: 6%
- Cough: 6%
- Nausea: 5%
- Back pain: 5%
These are generally mild. Most people tolerate Vemlidy well enough to continue long-term therapy without interruption.
Serious Risks to Know About
Vemlidy carries two boxed warnings from the FDA, which signal the most serious potential dangers.
The first involves what happens when you stop taking it. Discontinuing Vemlidy (or any hepatitis B antiviral) can cause a severe flare of hepatitis B. The virus, no longer suppressed, rebounds rapidly, and the immune system’s response can cause sudden, serious liver inflammation. For this reason, liver function needs close monitoring for at least several months after stopping the drug. In some cases, restarting treatment becomes necessary.
The second warning concerns a rare but potentially fatal condition called lactic acidosis, where the body accumulates too much lactic acid. This has been reported with drugs in the same class. It can occur alongside severe liver enlargement and fatty liver. Treatment should be stopped if signs of either condition appear.
Who Should Not Take Vemlidy
Vemlidy is not recommended for patients with decompensated liver disease, meaning those whose liver has already lost significant function (classified as Child-Pugh B or C). It is also not appropriate for patients with end-stage kidney disease who are not on regular hemodialysis.
Several drug interactions can make Vemlidy less effective or increase its side effects. Certain seizure medications (carbamazepine, phenytoin, phenobarbital, oxcarbazepine), tuberculosis drugs (rifampicin, rifabutin, rifapentine), and the herbal supplement St. John’s wort all speed up the breakdown of Vemlidy in the body, potentially dropping its levels too low to suppress the virus. On the other end, strong antifungal medications like itraconazole and ketoconazole can raise Vemlidy levels too high. Several HIV protease inhibitor combinations are also incompatible. You should not take Vemlidy alongside any other medication that already contains tenofovir or the related drug adefovir.
Ongoing Monitoring While on Treatment
Because Vemlidy is a long-term medication, regular lab work is part of the treatment plan. Liver enzyme levels (ALT) should be checked every 3 to 6 months at minimum. Viral load (HBV DNA) is tested every 3 months while the virus is still detectable in the blood, then every 6 months once levels become undetectable. One advantage of Vemlidy over the older tenofovir formulation is that it requires less intensive kidney monitoring, though your provider will still check renal function periodically, especially if you have other risk factors for kidney problems.
The goal of treatment is sustained viral suppression: keeping HBV DNA at undetectable levels to prevent liver scarring, cirrhosis, and liver cancer. Vemlidy achieves this in the large majority of patients who take it consistently, but it requires commitment to daily dosing and regular follow-up appointments for the foreseeable future.